OncoMatch/Clinical Trials/NCT04486352
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Is NCT04486352 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for endometrial cancer.
Treatment: Atezolizumab - 28 Day Cycle · Bevacizumab · Ipatasertib · Talazoparib · Trastuzumab emtansine · Tiragolumab · Atezolizumab - 21 Day Cycle · Inavolisib · Letrozole · Giredestrant · Abemaciclib — This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Prior therapy
Cannot have received: T-cell costimulating or immune checkpoint blockade therapies (CD137 agonists, anti-PD-1, anti-PD-L1, anti-CTLA-4 therapeutic antibodies)
Prior treatment with T-cell costimulating or immune checkpoint blockade therapies including, but not limited to, CD137 agonists, anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic antibodies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Medstar Georgetown Cancer Institute · Washington D.C., District of Columbia
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- University of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify